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Rac-Driven Mesenchymal MigrationElongated mesenchymal migration of cancer cells is driven by Rac1 activation
mediated by the adaptor NEDD9 and the exchange factor DOCK3. A new study
reports a role for the transcription factor Twist1 in inducing mesenchymal
migration by relieving the suppression of NEDD9 and DOCK3 by the microRNA
let-7i.Victoria Sanz-Moreno
The epithelial–mesenchymal transition
(EMT) is a highly conserved and
fundamental process that governs
morphogenesis in multicellular
organisms and is thought to promote
metastatic progression of carcinomas
[1]. Some key events typical of EMT are
loss of the cell–cell adhesion molecule
E-cadherin, gain of N-cadherin and
augmented expression of certain
transcription factors. EMT leads to loss
of cell–cell adhesion and increased cell
migration and invasion [1]. Twist1,
a transcriptional regulator, induces
EMT by suppression of E-cadherin [2].
A recent paper by Yang et al. [3] now
reveals that Twist1 is a key regulator of
elongated mesenchymal migration of
cancer cells through regulation
of a microRNA (miRNA) that
controls signalling by the Rho-family
GTPase Rac.
Rho-family GTPases are key
regulatorsof cellmigration through their
actions on actin assembly and
actomyosin contractility. Cells can
migrate as collective groups or as
individualcells. Twomodesof individualcell migration have been characterized
in a number of systems. An elongated
(‘mesenchymal-like’) mode is
characterized by cell polarization,
a requirement for extracellular
proteolysis [4], and low actomyosin
contractility [5], and is driven by the
formationofmembraneprotrusions that
result from a localized activation of the
Rac GTPase [6]. Rounded ‘amoeboid’
modes of cell migration are driven by
high levels of actomyosin contractility
regulated by Rho–ROCK signalling [5,7]
or the Cdc42 GTPase [8]. In rounded
moving cells, high hydrostatic forces
drive cell movement resulting in
membrane blebbing [9]. Interestingly,
Cdc42 is capable of regulating
elongated mesenchymal or rounded
contractile movement via usage of
different guanine nucleotide exchange
factors (GEFs) [8].
Elongated mesenchymal movement
can be driven by activation of Rac1
through the GEF DOCK3 complexed
with the adaptor protein NEDD9 [5].
Rac1 promotes elongation through
WAVE2-mediated actin polymerization
[5,10,11]. Furthermore, Rac1 signalling
suppresses rounded movement[5,11,12] through decreasing
actomyosin contractility [5,12]. In an
effort to identify new functions of
Twist1, Yang et al. [3] screened for
possible new targets with a particular
focus on miRNAs. They reasoned that
Twist1 cooperates with the Polycomb
group protein BMI1 [2] and they
selected head and neck squamous
cell carcinoma (HNSCC) cell lines that
would have different expression
levels of the Twist1–BMI1 pairing to
compare their migratory behaviour.
The authors performed microarray
analysis to identify which miRNAs
were co-regulated by both Twist1 and
BMI1 and found that these proteins
co-repressed let-7i miRNA [3]. The
authors confirmed that loss of let-7i
induced a morphological switch into
a mesenchymal program of invasion
[3], with long-lived protrusions that are
typical of a Rac-driven phenotype.
They went on to find that let-7i
downregulated NEDD9 and DOCK3
[3], both of which are activators of
Rac and drive mesenchymal
movement in several systems
[3,5,10,12]. Furthermore, Twist1
overexpression induced Rac1
activation in HNSCCs, as a result of
increased expression of both NEDD9
and DOCK3 [3] (Figure 1).
Interestingly, other miRNAs have been
shown to regulate mesenchymal
migration: miR-200 family members
can regulate the plasticity of tumour
cell movement [13] and the miR-200c
target MARCKS is capable of
regulating mesenchymal invasion by

























Figure 1. Rac GTPase signalling in elongated mesenchymal cancer cell migration and
invasion.
In elongated mesenchymal migrating cells, Twist1 and BMI1 mediate suppression of the
miRNA let-7i, which results in NEDD9 and DOCK3 overexpression in HNSCC [3]. NEDD9 over-
expression promotes elongated mesenchymal motility in HNSCC [3], melanoma [5,12] and
breast cancer [16]. NEDD9 and DOCK3 have been reported to cooperate in order to activate
Rac1 and drive mesenchymal migration in HNSCC [3] and melanoma [5,10,12]. WAVE2, acting
downstream of Rac, drives mesenchymal migration by promoting actin assembly to form
cellular protrusions in melanoma [5,10], glioblastoma [11] and fibrosarcoma [11]. In melanoma
cells, NEDD9 acts through integrin b3 and Src to promote mesenchymal migration, as Src
inhibits ROCK2-dependent rounded amoeboid invasion [12]. Cdc42 activation controls elon-
gated mesenchymal migration in melanoma [8] via an unknown guanine nucleotide exchange
factor (GEF).
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R450HNSCC tends to remain localized at
the primary site and regional lymph
nodes. Severe local tissue destruction
with a low frequency of distal organ
metastasis is observed in HNSCC
patients [14]. To translate their
observations to the clinical setting,
Yang et al. [3] made the interesting
observation that decreasing amounts
of let-7i are present in a cohort of
HNSCC patients with tumours that
have invaded adjacent tissues.
Yang et al. [3] find that the
Twist–let-7i–NEDD9–DOCK3 axis has
prognostic value for HNSCC [3].
NEDD9 had already been found to
be overexpressed during human
melanoma progression [15] and was
found to be a marker for elongated
mesenchymal motility in human
melanoma samples [12]. NEDD9 has
also been found to regulate cellular
protrusive activity in breast cancer
models [16]. All of these studies point
to NEDD9 being a bona fidemesenchymal marker, a proposal that
will now need to be explored in more
malignancies that use mesenchymal
invasion strategies.
The question that arises is how
NEDD9 might function in invasion and
metastasis. It is a member of the
p130Cas family and has multiple
partners [17], so it is likely to have
multiple roles, in addition to the
regulation of Rac activation through
DOCK3. Recent work has reported
that NEDD9 drives elongation and
mesenchymal invasion in melanoma
via engagement of integrin avb3 and
recruitment of Src kinase [12]. A key
role of NEDD9-dependent Src
signalling is to suppress ROCK2,
which otherwise would drive high
actomyosin contractility [12] (Figure 1)
that would in turn suppress
Rac-dependent mesenchymal
movement [5,10,12].
In the course of their experiments
Yang et al. [3] describe cells witha rounded morphology. One should be
careful when addressing amoeboid
phenotypes as several types of
amoeboid migration have been
described to date [18]. In the case of
cancer cells, rounded amoeboid
contractile movement is characterized
by intensive blebbing. Blebs formwhen
the plasmamembrane detaches focally
from the underlying actin filament
cortex [19], allowing cytoplasmic flow
to push the membrane outwards
rapidly due to hydrostatic pressure in
the cell interior. This high blebbing is
regulated by Rho–ROCK signalling [7,9]
and is characterized by high levels of
phosphorylated myosin light chain II
(MLC) [5,12,13]. The round cells
described in the study from Yang et al.
[3] lack blebs and instead display short
protrusions. Furthermore, the levels of
Rho-GTP or phospho-MLC in these
round cells are no different, or in fact
lower, than in the elongated cells
considered in their study [3]. It is likely
that the round cells described in [3] are
different from round ‘amoeboid-like’
migrating cells [5,7–9,12,13].
Nevertheless, the authors show in very
thorough manner that manipulations of
Twist1 and let-7i can lead to opposite
results in terms of how they regulate
elongated mesenchymal migration [3].
Twist1 positively impinges on cell
elongation and invasion, and let-7i
suppresses it by inhibiting DOCK3 and
NEDD9 expression. Another important
finding in this study is the fact that
suppression of let-7i promotes
tumour-initiating capabilities without
affecting EMT [3]. It would be
interesting to assess whether NEDD9,
DOCK3 and Rac1 are involved in
tumour initiation or whether it is an
independent biological effect derived
from let-7i suppression that does not
require the Rac signalling axis.
Yang et al. [3] have described how
mechanisms of HNSCC dissemination
rely greatly on mesenchymal invasion
and its key players NEDD9, DOCK3
and Rac1 [3], insights that could be
useful in the treatment of HSNCC
patients. Targeting just one invasive
strategy could be an approach against
malignancies that do not metastasize
so readily and that only use
mesenchymal migration, as in the case
of HSNCC. Interestingly Yang et al. [3]
did not find any correlation with let-7i
expression in human metastatic
HNSCC specimens, suggesting that
HNSCC metastasis may depend on
different mechanisms compared with
Dispatch
R451HNSCC local invasion. Tumours like
melanomas, which are highly
metastatic [20], may use both
elongated mesenchymal and rounded
amoeboid-like contractile invasion
strategies in order to disseminate more
efficiently. This plasticity could allow
the tumour cell to cope with different
environments using a larger repertoire
of invasive strategies. Following this
line of argument, melanoma patients
should be treated with a combination
of drugs that inhibit both rounded
amoeboid and elongated
mesenchymal types of movement
[5,7,8,12]. Other tumour types, such as
glioblastomas and fibrosarcomas,
have been reported to show similar
plasticity [11]; therefore, blocking both
strategies would also be necessary in
order to stop their invasion and/or
metastasis [11]. The challenge for the
next few years will be to validate
tumour invasion signatures as
prognosis markers and to find good
therapeutic targets within such
signatures.
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ExistTwoprocessessuggested todrivebacterial speciation—periodicselectionand
recombination — are generally thought to be mutually opposed. Recent work
shows that data taken as evidence supporting the former may be explained by
the latter, raising further problems for the idea of bacterial ‘species’.W. Ford Doolittle
The concept of species is famously
difficult, especially for bacteria. Mayr’s
‘Biological Species Concept’ — that
species are interbreeding groups
separated from other such groups by
reproductive barriers — would not
apply to bacteria at all if, as once
believed, they are always asexual,
never recombining genetically.
Obviously, though not trivially, therewould be no ‘interbreeding’. But some
authors maintain that even asexual,
non-recombining clones can mimic
‘biological species’ in important ways.
Specifically, ecologically differentiated
clonal organisms can maintain
relatively constant within-population
genomic and phenomic similarity
(cohesion) over time, while exhibiting
increasing between-population
divergence. An important driver in this
ecotype model [1] is periodic selection,the operation of which seemed to be
favored by earlier data from several
groups, including theMIT labs ofMartin
Polz and Eric Alm. But now these
workers offer a serious challenge to the
model [2].
Periodic selection, first understood
through the chemostat experiments
of Kim Atwood [3], is what happens
when, in a finite population of
non-recombining organisms in a stable
niche, amutant arises that is better able
to use the niche’s resources. Through
selection, all organisms in the
population will eventually be the direct
descendants of this favored mutant
ancestor. And because there is no
recombination, their genomes will bear
at all loci only direct lineal descendants
of those specific alleles the lucky
mutant happened to have in its genome
at the time.
Populations will thus be ‘purged’ of
all allelic diversity accumulated before
